UPDATE 1-Catalent to buy Paragon Bioservices for $1.2 bln -WSJ

Drug developer Catalent Inc has agreed to buy privately held, gene-therapy focused Paragon Bioservices Inc for $1.2 billion, the Wall Street Journal reported on Sunday, citing people familiar with the matter.